Retrospective Survey of Bone Fracture in Patients With Arimidex 1mg

Completed

• Conditions: Breast Cancer

• Registration Number: NCT00859560
• Lead Sponsor: AstraZeneca

Brief Summary

The retrospective survey is to investigate the incidence of bone fracture in post-menopausal breast cancer patients with Arimidex 1mg, who were previously registered for the clinical experience investigation.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-01
• Study Completion: 2008-12
• Status Verified: 2009-03
• Study First Submitted: 2009-03-10
• Study First Submitted QC: 2009-03-10
• Last Update Submitted: 2009-03-10
• Study First Posted: 2009-03-11
• Last Update Posted: 2009-03-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 2205

Inclusion Criteria

• Post-menopausal breast cancer patients treated with Arimidex 1mg at the time of previously conducted clinical experience investigation.

Exclusion Criteria

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Bone fracture incidence	Time since starting Arimidex

Secondary Outcome Measures

Name	Time	Method
Bone density measurement	Time since starting Arimidex
Survival	Time since starting Arimidex